Individualized therapy in non-small-cell lung cancer: future versus current clinical practice (Q37579648)

21 August 2017

1 reference

title

Individualized therapy in non-small-cell lung cancer: future versus current clinical practice (English)

1 reference

21 August 2017

1 reference

R Pérez-Soler

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

28 Suppl 1

1 reference

21 August 2017

page(s)

S38-45

1 reference

Mass spectrometry-based proteomics

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Gene ontology: tool for the unification of biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Gene-expression profiles predict survival of patients with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Protein profiles associated with survival in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

An overview of lung cancer genomics and proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Mutational analysis of the class I beta-tubulin gene in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Proteomics: current techniques and potential applications to lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Tailor-made chemotherapy for non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Proteomics analysis in lung cancer: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

21 January 2018

Assessing EGFR mutations

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Prognostic versus predictive value of biomarkers in oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Data analysis--the Achilles heel of proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Prognostic factors in non‐small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Considerations for second-line therapy of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

HKI-272 in non small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Proteomic patterns of tumour subsets in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

KRASMutation Signature in Colorectal Tumors Significantly Overlaps With the Cetuximab Response Signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

Peptide mass fingerprinting: protein identification using MALDI-TOF mass spectrometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.200

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.200

1 reference

21 August 2017

1 reference